S'abonner

Identification of checkpoints in human T-cell development using severe combined immunodeficiency stem cells - 05/02/16

Doi : 10.1016/j.jaci.2015.08.022 
Anna-Sophia Wiekmeijer, MSc a, Karin Pike-Overzet, PhD a, Hanna IJspeert, PhD b, Martijn H. Brugman, PhD a, Ingrid L.M. Wolvers-Tettero, BSc b, Arjan C. Lankester, MD, PhD c, Robbert G.M. Bredius, MD, PhD c, Jacques J.M. van Dongen, MD, PhD b, Willem E. Fibbe, MD, PhD a, Anton W. Langerak, PhD b, Mirjam van der Burg, PhD b, Frank J.T. Staal, PhD a,
a Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands 
c Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands 
b Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands 

Corresponding author: Frank J. T. Staal, PhD, Department of Immunohematology and Blood Transfusion, L3-35, Leiden University Medical Center, PO Box 9600, 2300 RC/Leiden, The Netherlands.

Abstract

Background

Severe combined immunodeficiency (SCID) represents congenital disorders characterized by a deficiency of T cells caused by arrested development in the thymus. Yet the nature of these developmental blocks has remained elusive because of the difficulty of taking thymic biopsy specimens from affected children.

Objective

We sought to identify the stages of arrest in human T-cell development caused by various major types of SCID.

Methods

We performed transplantation of SCID CD34+ bone marrow stem/progenitor cells into an optimized NSG xenograft mouse model, followed by detailed phenotypic and molecular characterization using flow cytometry, immunoglobulin and T-cell receptor spectratyping, and deep sequencing of immunoglobulin heavy chain (IGH) and T-cell receptor δ (TRD) loci.

Results

Arrests in T-cell development caused by mutations in IL-7 receptor α (IL7RA) and IL-2 receptor γ (IL2RG) were observed at the most immature thymocytes much earlier than expected based on gene expression profiling of human thymocyte subsets and studies with corresponding mouse mutants. T-cell receptor rearrangements were functionally required at the CD4CD8CD7+CD5+ stage given the developmental block and extent of rearrangements in mice transplanted with Artemis-SCID cells. The xenograft model used is not informative for adenosine deaminase–SCID, whereas hypomorphic mutations lead to less severe arrests in development.

Conclusion

Transplanting CD34+ stem cells from patients with SCID into a xenograft mouse model provides previously unattainable insight into human T-cell development and functionally identifies the arrest in thymic development caused by several SCID mutations.

Le texte complet de cet article est disponible en PDF.

Key words : SCID, thymus, NSG, IL2RG, IL7RA, adenosine deaminase, Artemis, T-cell development, B-cell development

Abbreviations used : ADA, BM, DN, HSPC, IGH, IL2RG, IL7RA, IMDM, LUMC, NK, NSG, SCID, TCR, TRD, UCB


Plan


 Supported by KiKa (Children Cancer Free, grant no. 36), ZonMW E-RARE (grant no. 40-41900-98-020), NWO (Vidi grant no. 91712323) and the Netherlands Institute for Regenerative Medicine (NIRM).
 Disclosure of potential conflict of interest: A.-S. Wiekmeijer has received her salary and travel support from a grant provided by KIKA. J. J. M. van Dongen has consultant arrangements with Roche; has received payment for lectures from BD Biosciences and Pfizer; has patents with and receives royalties from DAKO, InVivoScribe, BD Biosciences, Cytognos, and Immunostep; and has received travel support from Roche and BD Biosciences. W. E. Fibbe has received an H2020 grant. M. van der Burg has received a grant from ZonMW Vidi (9.171.2323). F. J. T. Staal has received research support from KIKA and the European Union; has received travel support from ZonMw SCID gene therapy grants and the European Union; and is employed by Leiden University Medical Center. The rest of the authors declare that they have no relevant conflicts of interest.


© 2015  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 137 - N° 2

P. 517 - février 2016 Retour au numéro
Article précédent Article précédent
  • Extracellular vesicle–derived protein from Bifidobacterium longum alleviates food allergy through mast cell suppression
  • Jung-Hwan Kim, Eun-Ji Jeun, Chun-Pyo Hong, Seong-Hoon Kim, Min Seong Jang, Eun-Jung Lee, Sook Jin Moon, Chang Ho Yun, Sin-Hyeog Im, Seok-Geun Jeong, Beom-Young Park, Kyong-Tai Kim, Ju-Young Seoh, Yoon-Keun Kim, Sung-Jong Oh, Jun-Sang Ham, Bo-Gie Yang, Myoung Ho Jang
| Article suivant Article suivant
  • Exposure to welding fumes and lower airway infection with Streptococcus pneumoniae
  • Reetika Suri, Jimstan Periselneris, Sophie Lanone, Patti C. Zeidler-Erdely, Geoffrey Melton, Keith T. Palmer, Pascal Andujar, James M. Antonini, Vanessa Cohignac, Aaron Erdely, Ricardo J. Jose, Ian Mudway, Jeremy Brown, Jonathan Grigg

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.